Every day, physicians and patients face a barrier that has nothing to do with clinical need and everything to do with administrative process: the prior authorization (PA). For specialty medications to treat complex, chronic conditions, prior authorizations have become one of the most significant obstacles to timely, effective care. The consequences aren't just frustrating; they're harmful.
Ask any specialty practice administrator what consumes the most non-clinical time in their week, and the answer is almost always the same: prior authorizations.
The process is manual, repetitive, and relentless. A physician prescribes a specialty medication based on clinical evidence and patient need. What follows is a cascade of paperwork, phone calls, faxes, and waiting before a single dose is dispensed. Staff must gather clinical documentation, submit requests to payers, respond to denials, provide additional information, and manage appeals, all while keeping up with everything else a busy practice demands.
According to the American Medical Association’s 2024 survey, practices complete an average of 43 prior authorizations per physician per week, with physicians and staff spending 12 hours each week on PA requests alone. The administrative burden costs more than $68,000 per physician annually in staff time. [1] And 95% of physicians report that the process somewhat or significantly contributes to burnout. [1] In specialty care, where the clinical complexity is highest and the medications most critical, the impact is even more pronounced. When a prior authorization is denied or approval is delayed, the consequences fall hardest on the patient.
For patients prescribed specialty medications, every day of delay matters. These are often people managing autoimmune conditions, neurological disorders, rare diseases, or oncology diagnoses. They've already been through the process of getting a diagnosis, seeing a specialist, and receiving a treatment plan. Prior authorization can put their care on hold for days, weeks, or even months.
Industry estimates suggest that specialty medications typically require 10 to 30 or more days for PA approval compared to just one to three business days for standard medications with complete paperwork. The AMA's 2023 survey found that 94% of physicians reported care delays due to PAs, and 24% reported that PA has led to serious adverse patient outcomes, including hospitalization, disability, and death. [2] Across specialties, the data is both consistent and troubling.
In rheumatology, PA requirements for infusible biologics delayed treatment to a median of 31 days and when initial PAs were denied, the wait extended to a median of 50 days, with denied patients receiving nearly four times more glucocorticoid exposure in the following three months compared to patients whose medications required no prior authorization. Critically, 96% of all PAs were ultimately approved, raising serious questions about the value of the process. [3]
In gastroenterology, PA delays averaged seven days for biologics and extended to 29 days when an appeal was required. More than half of IBD patients had their first dose of advanced therapy delayed by more than two weeks. In pediatric IBD, complicated PAs added nearly 25 days to biologic initiation time and increased IBD-related healthcare utilization by nearly 13%. [4-5]
In dermatology, mean PA processing took nearly 21 days when handled by provider offices compared to under two days when managed by specialty pharmacies. Private insurance patients waited the longest, with biologic approvals averaging 37 to 41 days depending on carrier. [6][7]
In neurology, headache specialists reported 10- to 14-day delays in appropriate treatment due to PA. For Parkinson disease psychosis, integrating a specialty pharmacist reduced pimavanserin PA approval time from 22 days to just three. In pediatric epilepsy, over a third of patients experienced at least one week of delay in accessing anti-seizure medications and 64% of those who missed doses due to PA delays experienced worsening seizures. [8]
The harm extends beyond delayed treatment. When patients face prolonged waits, confusing insurance requirements, and unexpected out-of-pocket costs, many simply give up. AMA survey data suggest that a large majority of physicians report patients abandoning their recommended course of treatment due to PA delays. [2]
In gastroenterology, more than half of surveyed physicians reported choosing inferior treatments at least weekly because of perceived PA burden, and half reported a patient who experienced serious adverse events due to PA-related care delays. [9]
In IBD specifically, patients who experienced PA-related delays had 2.24 times higher odds of requiring corticosteroid rescue and those denied a medication had 8.92 times higher odds of IBD-related surgery. [10]
The prior authorization system, as it exists today, was designed for a different era of healthcare. It has not kept pace with the complexity of specialty therapeutics, and patients are paying the price.
The data above make clear that PA delays are not merely administrative inconveniences — they produce measurable clinical harm across every major specialty. But the solution is not simply faster paperwork. Practices that control dispensing and infusion in-house are fundamentally better positioned to navigate PA requirements: they can initiate treatment the moment approval is obtained, eliminate handoff delays to external pharmacies, run financial assistance and benefits investigation in parallel with clinical workflows, and maintain direct oversight of the patient from prescription to first dose. This is the structural advantage that Medically Integrated Dispensing (MID) and In-Office Infusion (IOI) provide — and it is the foundation on which Elevate Health Technologies' OnePulse Connect platform was built.
Elevate Health Technologies' OnePulse Connect platform with Coverage Tracker was built to address this problem directly, operating in real time, from the moment a prescription is written. When a healthcare provider sends an electronic prescription, OnePulse Connect instantly receives it along with full patient information through integrations with existing practice management and EHR systems. There is no manual data re-entry, no lag, and no missing information. The process starts immediately and accurately.
From there, our team initiates a full Benefits Investigation. Coverage gaps are identified upfront, reducing the risk of abandonment later. Prior authorization requirements specific to each payer are flagged before they become bottlenecks. Financial assistance and copay program eligibility are surfaced right away, so patients are presented with the lowest possible out-of-pocket cost from the start and not as an afterthought.
If a prior authorization is needed, Coverage Tracker activates an expedited process. We work directly with the healthcare provider to complete a pre-populated PA request, dramatically reducing the administrative lift on practice staff and accelerating turnaround time. If no PA is required, the patient moves forward immediately with no unnecessary delays. Financial assistance enrollment runs in parallel, so nothing is waiting for anything else.
Once coverage is confirmed, our team coordinates patient outreach via SMS/text, or phone. Patients receive education about their medication, their condition, and what to expect from treatment. This layer of engagement improves adherence and reduces the anxiety that too often leads to treatment abandonment.
Through In-Office Dispensing, medications are accessible to patients from their single trusted site of care: their provider's office. This keeps treatment within the physician's clinical setting, where oversight is strongest and continuity of care is greatest. And throughout the entire process, the OnePulse Connect platform provides robust data insights including dispensing compliance, patient adherence, and adverse event tracking monitored in near real-time, giving practices the visibility they need to intervene early when patients are at risk.
The OnePulse Connect platform is built on two clinically validated care delivery approaches: Medically Integrated Dispensing (MID) and In-Office Infusion (IOI). The evidence supporting these models is growing, and it spans the specialties we serve.
An integrated health-system specialty pharmacy achieved a median time to treatment of 12 days, compared to 18 days for external specialty pharmacies. Once medication was ready to fill, patients at the integrated pharmacy received it in two days versus 12 days externally. [11] In dermatology specifically, embedding a pharmacist in-clinic reduced average time to medication initiation from 21.3 days to 13.6 days. [12] A centralized PA processing center within a health-system specialty pharmacy has also been shown to decrease delays in therapy initiation while increasing patient and provider satisfaction. [13]
Medicare Part D beneficiaries using specialty pharmacies for TNF inhibitor therapies (the backbone of treatment across rheumatology, gastroenterology, and dermatology) had 55% higher odds of adherence compared to retail pharmacy users. [14] External specialty pharmacies showed 60% higher odds of primary medication nonadherence compared to integrated health-system pharmacies. [15] In oncology, a MID pilot program demonstrated significantly lower discontinuation rates (29% vs. 48%, p=0.01) and significantly less drug waste ($937 vs. $2,733 per dose change) compared to centralized specialty pharmacies. [16]
A matched cohort study of more than 52,000 infusions across seven chronic conditions found that hospital outpatient department infusions carried 41.9% higher outpatient costs than physician offices and ambulatory infusion centers, with no significant differences in adverse events or outcomes. [17] An NEJM study found that hospital price markups for physician-administered drugs for inflammatory conditions were a median of 2.26 times acquisition cost at 340B hospitals, versus just 1.07 times at physician practices. [18] For commercially insured cancer patients, total per-patient costs were $115,843 in hospital outpatient departments versus $77,346 in physician offices, with no difference in evidence-based treatment selection. [19]
Specialty-specific outcomes reinforce the case. In gastroenterology, office-based infliximab infusions showed the highest probability of patients remaining on therapy at day 200 (79.3% compared to 74.2% in hospital settings and 64.4% at home). [20] In rheumatology, an Advanced Therapy Coordinator role reduced median wait time to advanced therapy initiation from 82 days to 49.5 days, demonstrating that even workflow coordination alone can cut delays by 40%. [21]
The adoption trajectory points clearly in one direction. By 2019, roughly 21% of gastroenterology practices and 22% of rheumatology practices were operating with in-house pharmacies. In oncology, where MID infrastructure is more mature, that figure was 63%, and the share of Medicare Part D spending on immunosuppressants filled at in-house pharmacies grew from 2% to 9% between 2011 and 2019. [22] The ASCO/NCODA joint standards for MID further validate this model, establishing evidence-based quality benchmarks for patient monitoring, education, adherence, and care coordination in the dispensing setting. [23] That gap represents both the scale of the opportunity and the urgency of the moment.
Elevate Health Technologies' OnePulse Connect platform doesn't just make prior authorizations faster, it condenses the entire journey between a written prescription and a patient's first dose.
For practice staff, it means fewer hours spent on phone queues and paperwork. For physicians, it means confidence that the treatments they prescribe will actually reach their patients. For patients, it means less waiting, less confusion, and better access to the medications they need to manage their health and quality of life.
The prior authorization problem isn't going away overnight. But with the right infrastructure in place, specialty practices don't have to absorb it alone. That's what Elevate Health Technologies' OnePulse Connect was built to do.
Click HERE to learn more about Elevate Health Technologies’ suite of technology-enabled capabilities and services, or to schedule a meeting.
Copyright © 2026 Elevate Health Technologies
